Pfizer Corporation

Erasca, Inc.

Agouron Pharmaceuticals, Inc.

Ping Chen

Cynthia Louise Palmer

Mehran Jalaie

Sajiv Krishnan Nair

Sacha Ninkovic

Suvi Tuula Marjukka Orr

Gary Michael Gallego

Robert Steven Kania

Hengmiao Cheng

Judith Gail Deal

Asako Nagata

Kevin Daniel Freeman-Cook

Eugene Yuanjin Rui

Douglas Carl Behenna

Sujin Cho-Schultz

Jun Feng

Jean-Michel Andre Vernier

John Charles Kath

Benjamin Jones

Andreas Maderna

Michael Raymond Collins

Robert Louis Hoffman

Maria Angelica Linton

Alexei Brooun

Simon Paul Planken

Jillian Elyse Spangler

Martha Alicia Ornelas

Marcos Gonzalez-Lopez

Nicholas A Isley

Kimberly O Cameron

Samit Kumar Bhattacharya

Mark Brian Anderson

Liying Zhang

John M Curto

Martin Youngjin Pettersson

Matthew Forrest Sammons

Mason Alan Pairish

Hong Shen

Qingyi Yang

Yajing Lian

Chun Luo

Patrick O'Connor

Luke Raymond Zehnder

Binh Nguyen

Smita Gaur

Ya-Li Deng

Chen Chen Kan

Karen Lundgren

Stephen Margosiak

James Register

Jay Sarup

Anna Tempczyk Russell

This invention relates to compounds of Formula (I)

Cyclin dependent kinase inhibitors

Tricyclic pyridones and pyrimidones

Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.

This invention relates to compounds of general Formula (I) 

CDK2/4/6 inhibitors

This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups Rto R, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

This invention relates to compounds of general Formula I in which A, R, R, Rand Rare as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.

Anti-proliferative agents for treating PAH

This invention relates to compounds of Formula (I) 

Compounds of the general formula: processes for the preparation of these compounds, compositions containing these compounds, and administration of these compounds to patients to treat pancreatic, lung, colon and other cancers.

Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents

Compounds of the general formula: processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Tetrahydroquinazoline derivatives useful as anticancer agents

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein X, Y, Z, R-R, m, n, and p are defined herein. The novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

Pyrimidine derivatives

The present invention relates to compounds of formula (X) 

Dihydropyrrolopyrimidine derivatives

The present invention relates to the identification, isolation and purification of the catalytic domain of the human effector checkpoint protein kinase (hChk1). A 1.7&angst; crystal structure of the hChk1 kinase domain in the active conformation is reported herein. The kinase domain of hChk1 and its associated crystal structure is described for use in the discovery, identification and characterization of inhibitors of hChk1. This structure provides a three-dimensional description of the binding site of the hChk1 for structure-based design of small molecule inhibitors thereof as therapeutic agents. Inhibitors of hChk1 find utility in the treatment of hyperproliferative disorders such as HIV and cancer.

Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof

Growing community of inventors

San Diego, CA, United States of America

Ping Chen